Skip to content

house · Committee report

H. Rept. 119-733

ACCELERATING ACCESS TO CRITICAL THERAPIES FOR ALS REAUTHORIZATION ACT OF 2026

2026-07-09

Committees

Associated legislation

Text

Purpose and Summary

H.R. 8205, introduced on April 6, 2026, by Representatives Mike Quigley (D-IL) and Ken Calvert (R-CA), reauthorizes the ``Accelerating Access to Critical Therapies for ALS Reauthorization Act'' or ``ACT for ALS.'' This extends appropriations for the ALS grant program, the public-private partnership for rare neurodegenerative diseases, the rare neurodegenerative disease action plan and the rare neurodegenerative disease grant program through fiscal year 2031.

Background and Need for Legislation

Recent estimates indicate that about 35,000 people in the United States are living with amyotrophic lateral sclerosis (ALS) and there are more than 5,000 new cases diagnosed each year.\1\ --------------------------------------------------------------------------- \1\Ctrs. for Disease Control and Prevention (CDC), National Amyotrophic Lateral Sclerosis (ALS) Registry, About the National ALS Registry (May 4, 2026), https://www.cdc.gov/als/abouttheregistrymain/ index.html. --------------------------------------------------------------------------- ALS, also known as Lou Gehrig's disease, is a degenerative neurological condition that affects the function of motor neurons, or nerve cells in the brain and spinal cord, that control voluntary muscle movement and breathing.\2\ Early signs and symptoms of the disease include, but are not limited to, difficulty chewing or swallowing, slurred speech, tight and stiff muscles, as well as muscular twitching, weakness, and cramping.\3\ Throughout the disease progression, muscle weakness and atrophy spread to other areas of the body, causing people with ALS to experience further difficulty with forming words and speaking, breathing, and maintaining a healthy weight, among other symptoms.\4\ Roughly 10 percent of ALS cases are genetic, while the rest are considered sporadic.\5\ Most individuals only survive 2 to 5 years post-diagnosis, though progression varies.\6\ --------------------------------------------------------------------------- \2\Nat'l Insts. of Neurological Disorders and Stroke, Amyotrophic Lateral Sclerosis (ALS), (Mar. 13, 2026), https://www.ninds.nih.gov/ health-information/disorders/amyotrophic- lateral-sclerosis-als. \3\Id. \4\Id. \5\Id. \6\Government Accountability Office (GAO), Rare Diseases: Funding for Rare Neurodegenerative Disease Research and Access to ALS Investigational Drugs, GAO-26-107691 at 7 (Feb. 4, 2026), https:// www.gao.gov/products/gao-26-107691. --------------------------------------------------------------------------- On average, it takes between 10 to 16 months to diagnose ALS after the onset of symptoms.\7\ Accordingly, many individuals with ALS are ineligible to participate in clinical trials for investigational drugs due to those delays in diagnosis and the rapid progression of the disease.\8\ There is currently no cure for ALS.\9\ --------------------------------------------------------------------------- \7\Id. at 8. \8\Id. \9\GAO, supra note 6 at 1. --------------------------------------------------------------------------- In December 2021, the ACT for ALS Act was signed into law. Since then, it has supported research and development for therapies for ALS and other rare neurodegenerative conditions. The legislation aimed to improve access to therapies for individuals with ALS and other rare neurodegenerative diseases. To this end, the bill established a public-private partnership for rare neurodegenerative disease research and grant programs, through which sponsors of investigational interventions and public and private entities could be awarded grants to support research and development of interventions, patient access to investigational ALS therapies, and agreements to advance the understanding of neurodegenerative diseases.\10\ Congress allocated funding for these three programs to the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) through the annual Congressional appropriations process. The Act for ALS Act will expire on September 30, 2026. --------------------------------------------------------------------------- \10\Accelerating Access to Critical Therapies for ALS Act, Pub. L. No. 117-79, 135 Stat. 1533, (2021). ---------------------------------------------------------------------------

Committee Action

On April 15, 2026, the Subcommittee on Health held a legislative hearing on H.R. 8205. The title of the hearing was ``Healthier America: Legislative Proposals to Improve Public Health.'' The Subcommittee received testimony from: Jamie Ulmer, MA, President and CEO, Healthcare Network; Rachel F. Brem, MD, FACR, FSBI, Co-Founder, Chief Medical Officer, Brem Foundation to Defeat Breast Cancer and Professor and Vice-Chair Emeritus, The George Washington University; Holly Ahern, MS, MT (ASCP), Associate Professor of Microbiology, State University of New York Adirondack; Amy L. Ronneberg, MBA, Chief Executive Officer, National Marrow Donor Program; Brian Wallach & Sandra Abrevaya, Co- Founders, I AM ALS; and Rene Qashie, JD, Vice President, Digital Health, Consumer Technology Association. On May 13, 2026, the Subcommittee on Health met in open markup session and forwarded H.R. 8205, as amended, to the full Committee by a voice vote. On May 21, 2026, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 8205, as amended, favorably reported to the House by a record vote of 46 yeas and 0 nays.

Committee Votes

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 8205 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to reauthorize and make changes to the grant award authority, expanded access program, and public-private partnership for research on therapies for ALS and other neurodegenerative diseases. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 8205 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearing was used to develop or consider H.R. 8205: On April 15, 2026, the Subcommittee on Health held a legislative hearing on H.R. 8205. The title of the hearing was ``Healthier America: Legislative Proposals to Improve Public Health.'' The Subcommittee received testimony from: Jamie Ulmer, MA, President and Chief Executive, Healthcare Network; Rachel F. Brem, MD, FACR, FSBI, Co-Founder, Chief Medical Officer, Brem Foundation to Defeat Breast Cancer and Professor and Vice-Chair Emeritus, The George Washington University; Holly Ahern, MS, MT (ASCP), Associate Professor of Microbiology, State University of New York Adirondack; Amy L. Ronneberg, MBA, Chief Executive Officer, National Marrow Donor Program; Brian Wallach & Sandra Abrevaya, Co-Founders, I AM ALS; and Rene Quashie, JD, Vice President, Digital Health, Consumer Technology Association. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 8205 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Short title Section 1 provides for a short title of ``Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.'' Section 2. Reauthorization of Accelerating Access to Critical Therapies for ALS Act Section 2 reauthorizes the Accelerating Access to Critical Therapies for ALS Reauthorization Act through 2031. Section 3. Improvements to program for grants for research on therapies for ALS Section 3 amends the ALS grant program to improve the requirements for participation. authorizes It requires the Secretary of Health and Human Services to request from the manufacturer or sponsor of an investigational drug certain data related to enrollment, safety, and efficacy, for the purpose of reviewing an application for renewal of a grant awarded under this section. It also requires entities seeking a grant to report any new and serious adverse events and patient safety data related to its phase 3 clinical trials if considered unexpected. Finally, this section clarifies that combined phase 2/3 clinical trials that begin enrollment within a predetermined timeframe may be considered eligible clinical trials under this section. Section 4. FDA rare neurodegenerative disease action plan Section 4 directs FDA to publish, not later than 18 months after the date of enactment, an action plan describing activities the agency intends to take during the 5 years after the plan's publication to implement program enhancements, policy development, regulatory science, and other initiatives to facilitate the development of and access to investigations drugs for ALS and other rare neurodegenerative diseases. This section also directs FDA to publish a report, not later than 5 years after the date of enactment, that describes actions taken to carry out the action plan. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): ACCELERATING ACCESS TO CRITICAL THERAPIES FOR ALS ACT * * * * * * * SEC. 2. GRANTS FOR RESEARCH ON THERAPIES FOR ALS. (a) In General.--The Secretary of Health and Human Services (referred to in this section as the ``Secretary'') shall award grants to participating entities for purposes of scientific research utilizing data from expanded access to investigational drugs for individuals who are not otherwise eligible for clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis. In the case of a participating entity seeking such a grant, an expanded access request must be submitted, and allowed to proceed by the Secretary, under section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb) and part 312 of title 21, Code of Federal Regulations (or any successor regulations), before the application for such grant is submitted. (b) Application.-- (1) In general.--A participating entity seeking a grant under this section shall submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary shall specify. (2) Use of data.--An application submitted under paragraph (1) shall include a description of how data generated through an expanded access request under section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb) with respect to the investigational drug involved will be used to support research or development related to the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis. (3) Noninterference with clinical trials.--An application submitted under paragraph (1) shall include a description of how the proposed expanded access program will be designed so as not to interfere with patient enrollment in ongoing clinical trials for investigational therapies for the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis. (4) Renewal of grants for research on therapies for als review.--In reviewing applications for renewals of a grant awarded under this section with respect to an investigational drug, the Secretary shall request from the manufacturer or sponsor, and assess, the enrollment, safety, and any available efficacy data relating to the investigational drug in the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis. (c) Selection.--Consistent with sections 406 and 492 of the Public Health Service Act (42 U.S.C. 284a, 289a), the Secretary shall, in determining whether to award a grant under this section, confirm that-- (1) such grant will be used to support a scientific research objective relating to the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis (as described in subsection (a)); (2) such grant shall not have the effect of diminishing eligibility for, or impeding enrollment of, ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis by determining that individuals who receive expanded access to investigational drugs through such a grant are not eligible for enrollment in-- (A) ongoing clinical trials that are registered on ClinicalTrials.gov (or successor website), with respect to a drug for the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis; or (B) clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis for which an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) has been granted by the Food and Drug Administration and which are expected to begin enrollment within one year; [and] (3) the resulting project funded by such grant will allow for equitable access to investigational drugs by minority and underserved populations[.]; and (4) the entity seeking such grant will promptly report any new and serious adverse events and safety information that is considered to be unexpected with respect to the phase 3 trial to the grant-making institution, in addition to complying with the safety reporting requirements under section 312.32 of title 21, Code of Federal Regulations (or any successor regulations). (d) Use of Funds.--A participating entity shall use funds received through the grant-- (1) to pay the manufacturer or sponsor for the direct costs of the investigational drug, as authorized under section 312.8(d) of title 21, Code of Federal Regulations (or successor regulations), to prevent, diagnose, mitigate, treat, or cure amyotrophic lateral sclerosis that is the subject of an expanded access request described in subsection (a), if such costs are justified as part of peer review of the grant; (2) for the entity's direct costs incurred in providing such drug consistent with the research mission of the grant; or (3) for the direct and indirect costs of the entity in conducting research with respect to such drug. (e) Definitions.--In this section: (1) The term ``participating entity'' means a participating clinical trial site or sites sponsored by a small business concern (as defined in section 3(a) of the Small Business Act (15 U.S.C. 632(a))) that is the sponsor of a drug that is the subject of an investigational new drug application under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) to prevent, diagnose, mitigate, treat, or cure amyotrophic lateral sclerosis. (2) The term ``participating clinical trial'' means a phase 3 clinical trial conducted pursuant to an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) or section 351(a) of the Public Health Service Act (42 U.S.C. 262(a)) to investigate a drug intended to prevent, diagnose, mitigate, treat, or cure amyotrophic lateral sclerosis. (3) The term ``participating clinical trial site'' means a health care facility, or network of facilities, at which patients participating in a participating clinical trial receive an investigational drug through such trial. (4) The term ``phase 3'', with respect to a clinical trial, includes a phase 2/3 combined trial that begins enrollment within a timeframe, determined by the Secretary through the terms and conditions of the grant awarded under this section. (f) Sunset.--The Secretary may not award grants under this section on or after September 30, [2026] 2031. * * * * * * * SEC. 4. [ALS AND OTHER RARE NEURODEGENERATIVE DISEASE ACTION PLAN] FDA RARE NEURODEGENERATIVE DISEASE ACTION PLAN. (a) In General.--Not later than 6 months after the date of enactment of this Act, the Commissioner of Food and Drugs shall publish on the website of the Food and Drug Administration an action plan describing actions the Food and Drug Administration intends to take during the 5-year period following publication of the plan with respect to program enhancements, policy development, regulatory science initiatives, and other appropriate initiatives to-- (1) foster the development of safe and effective drugs that improve or extend, or both, the lives of people living with amyotrophic lateral sclerosis and other rare neurodegenerative diseases; and (2) facilitate access to investigational drugs for amyotrophic lateral sclerosis and other rare neurodegenerative diseases. (b) Contents.--The initial action plan published under subsection (a) shall-- (1) identify appropriate representation from within the Food and Drug Administration to be responsible for implementation of such action plan; (2) include elements to facilitate-- (A) interactions and collaboration between the Food and Drug Administration, including the review centers thereof, and stakeholders including patients, sponsors, and the external biomedical research community; (B) consideration of cross-cutting clinical and regulatory policy issues, including consistency of regulatory advice and decisionmaking; (C) identification of key regulatory science and policy issues critical to advancing development of safe and effective drugs; and (D) enhancement of collaboration and engagement of the relevant centers and offices of the Food and Drug Administration with other operating divisions within the Department of Health and Human Services, the Partnership, and the broader neurodegenerative disease community; and (3) be subject to revision, as determined appropriate by the Secretary of Health and Human Services. (c) FDA Rare Neurodegenerative Disease Action Plan.-- (1) In general.--Not later than 18 months after the date of enactment of the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, the Commissioner of Food and Drugs shall publish on the website of the Food and Drug Administration an action plan that includes a description of the actions that the Food and Drug Administration intends to take during the 5-year period following publication of the action plan with respect to the program enhancements, policy development, regulatory science initiatives, and other appropriate initiatives described in subsection (a). (2) Report.--Not later than 5 years after the date of enactment of the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, the Commissioner of Food and Drugs shall publish on the website of the Food and Drug Administration a report that describes the actions taken by the Food and Drug Administration under the action plan published under paragraph (1) and the extent to which such action plan meets the requirements specified in paragraph (1). * * * * * * * SEC. 7. AUTHORIZATION OF APPROPRIATIONS. For purposes of carrying out this Act, there are authorized to be appropriated $100,000,000 for each of fiscal years 2022 through [2026] 2031. [all]

Source: https://api.congress.gov/v3/committee-report/119/hrpt/733